Susquehanna Fundamental Investments’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-18,100	Closed	-$226K	–	1550
2022 Q3	$226K	Buy	+18,100	New	+$207K	﹤0.01%	1231
2022 Q1	$227K	Sell	29,910 -58,420	-66%	-$554K	﹤0.01%	1329
2021 Q4	$902K	Buy	88,330 +38,310	+77%	+$488K	0.02%	694
2021 Q3	$671K	Buy	+50,020	New	+$815K	0.01%	1067
2021 Q2	–	Sell	-46,180	Closed	-$1.11M	–	1809
2021 Q1	$1.11M	Buy	+46,180	New	+$1.07M	0.02%	845

Other funds holding GTHX

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Susquehanna Fundamental Investments's GTHX Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2022, closing a stake of 18,100 shares — an estimated $226K sold.

Susquehanna Fundamental Investments first reported a position in GTHX in Q1 2021 and held it in 5 quarters. The position peaked at $1.11M in Q1 2021. 116 funds tracked by Wall St. Rank hold GTHX as of Q4 2022.

Susquehanna Fundamental Investments reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Susquehanna Fundamental Investments sold 18,100 G1 Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $226K.
Susquehanna Fundamental Investments first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Susquehanna Fundamental Investments's G1 Therapeutics, Inc. Common Stock position peaked at $1.11M in Q1 2021.
116 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.